Key result
Cardiac myosin inhibitors safely and rapidly improve quality of life and functional capacity in LVOTO.
Why the study?
Recent breakthroughs in hypertrophic cardiomyopathy have led to new precision cardiac myosin inhibitors, motivating an overview of the pivotal studies leading to mavacamten FDA approval and aficamten clinical development.
Do cardiac myosin inhibitors improve quality of life and functional capacity in patients with hypertrophic cardiomyopathy and left ventricular outflow tract obstruction?
Do cardiac myosin inhibitors improve quality of life and functional capacity in patients with hypertrophic cardiomyopathy and left ventricular outflow tract obstruction?
Cardiac myosin inhibitors represent a significant breakthrough in the treatment of hypertrophic cardiomyopathy, offering rapid improvements in quality of life and functional capacity comparable to optimal surgical results.
May support symptom relief in obstructive HCM; leaves open need for long-term randomized outcome data.
In the recent years, there has been a significant breakthrough in the treatment of hypertrophic cardiomyopathy. New precision molecules have been developed and successfully applied in clinical trials. A new class of orally available allosteric inhibitors reduces heart muscle hypercontractility, the core molecular defect of the disease, by selectively inhibiting cardiac beta-myosin. Based on the results obtained with the first two agents developed to date, mavacamten and aficamten, their use is safe and is associated with rapid and unprecedented improvement in quality of life and functional capacity in patients with left ventricular outflow tract obstruction, comparable to an optimal surgical result. This review provides an overview of the latest and most important studies that led to the approval of mavacamten by the U.S. Food and Drug Administration, and the clinical development of aficamten.
No takes yet. Share an insight, caveat, or question.
Pálinkás et al. (2023) conducted a review in Hypertrophic cardiomyopathy. Cardiac myosin inhibitors (mavacamten and aficamten) was evaluated. Cardiac myosin inhibitors (mavacamten and aficamten) safely provide rapid improvement in quality of life and functional capacity in patients with left ventricular outflow tract obstruction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: